NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
Neurogene Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$24.17+0.92 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $545.08M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.5%
17M of 20M shares
Institutional holders
112
22 new, 4 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 17 sales
Net sold $1.13M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker | 991,804 | 7.00% | 13G (passive) amendment | Jun 30, 2025 |
| Balyasny Asset Management L.P. | 818,706 | 5.18% | 13G (passive) | Jun 30, 2026 |
| Ortav Yehudai | 785,000 | 5.10% | 13G (passive) | Dec 8, 2025 |
| Prudential Financial Inc | 2,231,357 | 11.20% | 13G (passive) | Sep 30, 2026 |
| Jennison Associates LLC | 2,229,082 | 11.10% | 13G (passive) | Sep 30, 2026 |
| Samsara BioCapital GP, LLC | 1,717,127 | 11.60% | 13G (passive) amendment | Nov 25, 2024 |
| Jeremy C. Green | 1,572,202 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Redmile Group, LLC | 1,557,179 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| RTW Investments, LP | 1,498,829 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Oleg Nodelman | 1,442,902 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Eli Casdin | 1,295,361 | 8.70% | 13G (passive) amendment | Dec 31, 2024 |
| Rachel McMinn, Ph.D | 1,273,351 | 9.90% | 13D (active) | Dec 18, 2023 |
| BlackRock, Inc. | 1,011,436 | 6.80% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NGNE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Samsara BioCapital, LLC | 1,717,127 | 8.58% | $54.00M | – | 4.44% |
| Casdin Capital, LLC | 1,545,361 | 7.72% | $48.60M | +125,000 | 2.43% |
| Redmile Group, LLC | 1,412,199 | 7.06% | $44.41M | −47,400 | 2.98% |
| Rtw Investments, LP | 1,362,456 | 6.81% | $42.85M | – | 0.37% |
| EcoR1 Capital, LLC | 1,271,342 | 6.35% | $39.98M | – | 1.94% |
| BlackRock, Inc. | 1,057,983 | 5.29% | $33.27M | +52,913 | 0.00% |
| Baker Bros. Advisors LP | 991,691 | 4.96% | $31.19M | – | 0.16% |
| Balyasny Asset Management L.P. | 818,706 | 4.09% | $25.75M | +100,317 | 0.03% |
| Trails Edge Capital Partners, LP | 714,885 | 3.57% | $22.48M | −67,902 | 3.57% |
| Toronto Dominion Bank | 681,337 | 3.40% | $21.43M | – | 0.02% |
| Vanguard Capital Management LLC | 536,525 | 2.68% | $16.87M | +21,798 | 0.00% |
| Jennison Associates LLC | 518,582 | 2.59% | $16.31M | −9,103 | 0.01% |
| Citadel Advisors LLC | 408,982 | 2.04% | $12.86M | +21,951 | 0.00% |
| Great Point Partners LLC | 352,180 | 1.76% | $11.08M | −147,820 | 2.09% |
| ArrowMark Colorado Holdings LLC | 342,453 | 1.71% | $10.77M | −182,343 | 0.45% |
| FMR LLC | 295,561 | 1.48% | $9.30M | −87,086 | 0.00% |
| Geode Capital Management, LLC | 293,182 | 1.47% | $9.22M | +14,179 | 0.00% |
| State Street Corp | 224,322 | 1.12% | $7.05M | −88,683 | 0.00% |
| Franklin Resources Inc | 204,280 | 1.02% | $6.42M | New | 0.00% |
| Morgan Stanley | 191,724 | 0.96% | $6.03M | −93,515 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 112 | 17M | 86.5% | 22 / 38 | 31 / 4 | 1M | 1M |
| Q1 2026 | 96 | 17M | 84.8% | 19 / 43 | 16 / 15 | 2M | 1M |
| Q4 2025 | 93 | 17M | 82.5% | 14 / 24 | 29 / 7 | 2M | 1M |
| Q3 2025 | 88 | 15M | 76.5% | 16 / 24 | 25 / 10 | 1M | 1M |
| Q2 2025 | 82 | 15M | 76.9% | 9 / 27 | 29 / 12 | 1M | 2M |
| Q1 2025 | 85 | 16M | 82.2% | 15 / 29 | 24 / 17 | 2M | 2M |
| Q4 2024 | 88 | 16M | 80.4% | 28 / 30 | 17 / 25 | 5M | 3M |
| Q3 2024 | 86 | 14M | 69.2% | 23 / 22 | 22 / 2 | 3M | 1M |
| Q2 2024 | 66 | 13M | 66.7% | 22 / 21 | 14 / 16 | 2M | 2M |
| Q1 2024 | 60 | 13M | 65.8% | 32 / 11 | 10 / 7 | 4M | 1M |
| Q4 2023 | 35 | 10M | 48.2% | 35 / 0 | 0 / 0 | 10M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NGNE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 397,791 | 1.99% | $12.51M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 296,322 | 1.48% | $9.32M | 0.01% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 218,783 | 1.09% | $7.20M | 0.62% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 177,200 | 0.89% | $5.83M | 0.26% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 126,728 | 0.63% | $3.99M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 124,026 | 0.62% | $4.08M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 105,167 | 0.53% | $3.31M | 0.02% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 90,867 | 0.45% | $2.86M | 0.05% | Jun 30, 2026 |
| iShares Biotechnology ETF | 88,398 | 0.44% | $2.78M | 0.03% | Jun 30, 2026 |
| Meridian Small Cap Growth Fund | 75,859 | 0.38% | $2.39M | 0.87% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 57,993 | 0.29% | $1.64M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 55,794 | 0.28% | $1.58M | 0.00% | May 31, 2026 |
| Select Biotechnology Portfolio | 51,100 | 0.26% | $1.45M | 0.03% | May 31, 2026 |
| iShares Micro-Cap ETF | 37,552 | 0.19% | $1.18M | 0.08% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 27,503 | 0.14% | $904.57K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christine Mikail Cvijic | President and CFO, Director | 84,040 | 0.42% | Jul 7, 2026 |
| Rachel McMinn | Chief Executive Officer, Director | 1,344,307 | 6.72% | Mar 30, 2026 |
| Christina Shafer | Chief Commercial Officer | – | – | May 7, 2026 |
| Julie Jordan | Chief Medical Officer | 12,472 | 0.06% | Mar 30, 2026 |
| Stuart Cobb | Chief Scientific Officer | 30,497 | 0.15% | Mar 17, 2026 |
| Keith Woods | Director | – | – | Jun 16, 2026 |
| Sarah B. Noonberg | Director | – | – | Feb 24, 2026 |
| Rohan Palekar | Director | – | – | Feb 24, 2026 |
| Robert Baffi | Director | – | – | Feb 24, 2026 |
| Cory S. Freedland | Director | – | – | Feb 24, 2026 |
| Robert Keith Woods | Director | – | – | Jun 13, 2025 |
| Srinivas Akkaraju | 10% owner | 1,689,105 | 8.44% | Nov 27, 2024 |
| Samsara BioCapital GP, LLC | 10% owner | 1,668,357 | 8.34% | Nov 27, 2024 |
| Samsara BioCapital, L.P. | 10% owner | – | – | Nov 27, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Christine Mikail Cvijic President and CFO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −4,200 | $36.13 | $151.75K | 84,040 |
| Christine Mikail Cvijic President and CFO, Director | Jul 6, 2026 | Sale(10b5-1 plan) | −600 | $36.02 | $21.61K | 88,240 |
| Christine Mikail Cvijic President and CFO, Director | Jul 2, 2026 | Sale(10b5-1 plan) | −1,530 | $35.23 | $53.90K | 88,840 |
| Christine Mikail Cvijic President and CFO, Director | Jul 2, 2026 | Sale(10b5-1 plan) | −2,531 | $34.58 | $87.52K | 90,370 |
| Christine Mikail Cvijic President and CFO, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −739 | $34.06 | $25.17K | 92,901 |
| Christine Mikail Cvijic President and CFO, Director | May 6, 2026 | Sale(10b5-1 plan) | −4,800 | $30.07 | $144.34K | 98,440 |
| Christine Mikail Cvijic President and CFO, Director | May 6, 2026 | Sale(10b5-1 plan) | −4,800 | $32.44 | $155.71K | 93,640 |
| Rachel McMinn Chief Executive Officer, Director | Mar 26, 2026 | Sale(10b5-1 plan) | −3,352 | $22.07 | $73.98K | 1,344,307 |
| Julie Jordan Chief Medical Officer | Mar 26, 2026 | Sale(10b5-1 plan) | −828 | $21.89 | $18.12K | 12,472 |
| Christine Mikail Cvijic President and CFO | Mar 26, 2026 | Sale(10b5-1 plan) | −2,558 | $21.62 | $55.30K | 103,240 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −148 | $22.08 | $3.27K | 30,497 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −3,991 | $20.41 | $81.46K | 33,303 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2026 | Sale(10b5-1 plan) | −2,658 | $21.34 | $56.72K | 30,645 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2026 | Sale(10b5-1 plan) | −2,387 | $20.42 | $48.74K | 107,456 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2026 | Sale(10b5-1 plan) | −1,395 | $21.25 | $29.64K | 106,061 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2026 | Sale(10b5-1 plan) | −263 | $22.02 | $5.79K | 105,798 |
| Christine Mikail Cvijic President and CFO | Feb 27, 2026 | Sale(10b5-1 plan) | −4,800 | $25.11 | $120.53K | 109,843 |
| Stuart Cobb Chief Scientific Officer | Feb 20, 2026 | Award | +16,500 | – | – | 37,294 |
| Julie Jordan Chief Medical Officer | Feb 20, 2026 | Award | +4,900 | – | – | 13,300 |
| Christine Mikail Cvijic President and CFO | Feb 20, 2026 | Award | +22,000 | – | – | 114,643 |
| Rachel McMinn Chief Executive Officer, Director | Feb 20, 2026 | Award | +25,900 | – | – | 1,347,659 |
| Stuart Cobb Chief Scientific Officer | May 14, 2025 | Sale(10b5-1 plan) | −6,797 | $15.15 | $102.97K | 20,794 |
| Rachel McMinn Chief Executive Officer, Director | Mar 26, 2025 | Award | +23,900 | – | – | 1,274,259 |
| Julie Jordan Chief Medical Officer | Mar 26, 2025 | Award | +8,400 | – | – | 8,400 |
| Christine Mikail Cvijic President and CFO | Mar 26, 2025 | Award | +20,300 | – | – | 92,643 |
| Stuart Cobb Chief Scientific Officer | Mar 26, 2025 | Award | +7,200 | – | – | 27,591 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2025 | Sale(10b5-1 plan) | −4,501 | $16.94 | $76.25K | 72,343 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +20,748 | $24.91 | $516.83K | 1,689,105 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +10,803 | $26.01 | $280.99K | 1,699,908 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +15,219 | $26.73 | $406.80K | 1,715,127 |
| Srinivas Akkaraju 10% owner | Nov 26, 2024 | Buy | +2,000 | $27.50 | $55.00K | 1,717,127 |
| Christine Mikail Cvijic President and CFO | Nov 22, 2024 | Buy | +24,000 | $20.48 | $491.52K | 76,844 |
| Rachel McMinn Chief Executive Officer, Director | Nov 22, 2024 | Buy | +47,500 | $20.40 | $969.00K | 1,297,859 |
| Stuart Cobb Chief Scientific Officer | Mar 13, 2024 | Award | +20,391 | – | – | 20,391 |
| Christine Mikail Cvijic President and CFO | Mar 13, 2024 | Award | +31,903 | – | – | 52,844 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Oct 5, 2023 | Option exercise | +57,049 | – | – | 155,874 |
| Bros. Advisors (GP) LLC Baker Director, 10% owner | Oct 5, 2023 | Option exercise | +535,601 | – | – | 1,658,190 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +7,676 | $0.69 | $5.30K | 489,092 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +93,091 | $0.69 | $64.23K | 5,551,815 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +5,041 | $0.69 | $3.48K | 494,133 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 17, 2023 | Buy | +61,134 | $0.69 | $42.18K | 5,612,949 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +366 | $0.68 | $249 | 481,416 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +207,676 | $0.68 | $141.22K | 5,454,290 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +17,124 | $0.68 | $11.64K | 481,050 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 16, 2023 | Buy | +4,434 | $0.68 | $3.02K | 5,458,724 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +358 | $0.67 | $240 | 463,926 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +1,740,581 | $0.63 | $1.10M | 5,242,272 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +143,519 | $0.63 | $90.42K | 463,568 |
| Brothers Life Sciences LP Baker Director, 10% owner | Aug 15, 2023 | Buy | +4,342 | $0.67 | $2.91K | 5,246,614 |
| Sean Michael Smith Interim CFO, Prin Acct Off | Aug 11, 2023 | Sale | −1,323 | $0.62 | $820 | 21,637 |
| Sean Michael Smith Interim CFO, Prin Acct Off | Aug 10, 2023 | Option exercise | +5,000 | – | – | 22,960 |
| Priti Patel – | Apr 3, 2023 | Sale | −3,769 | $0.69 | $2.60K | 37,313 |
| Priti Patel – | Mar 31, 2023 | Option exercise | +10,000 | – | – | 41,082 |
| Priti Patel Chief Medical Officer | Feb 2, 2023 | Sale | −14,380 | $0.60 | $8.63K | 31,082 |
| Sean Michael Smith Principal Accounting Officer | Feb 2, 2023 | Sale | −3,316 | $0.60 | $1.99K | 15,960 |
| Priti Patel Chief Medical Officer | Feb 1, 2023 | Option exercise | +35,000 | – | – | 45,462 |
| Sean Michael Smith Principal Accounting Officer | Feb 1, 2023 | Option exercise | +12,500 | – | – | 19,276 |
| Sean Michael Smith Principal Accounting Officer | Aug 10, 2022 | Option exercise | +5,000 | – | – | 8,431 |
| Sean Michael Smith Principal Accounting Officer | Aug 10, 2022 | Sale | −1,655 | $0.99 | $1.64K | 6,776 |
| Priti Patel Chief Medical Officer | May 2, 2022 | Sale | −5,538 | $1.22 | $6.76K | 6,462 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Cvijic Christine Officer | May 6, 2026 | 14,400 | $416.74K | May 6, 2026 | Purchase |
| Cobb Stuart Officer | Mar 13, 2026 | 6,797 | $151.57K | Mar 13, 2026 | Restricted Stock Units |
| Cvijic Christine Officer | Feb 27, 2026 | 9,600 | $188.93K | Feb 27, 2026 | Purchase |
| Cobb Stuart Officer | May 14, 2025 | 6,797 | $105.42K | May 14, 2025 | Restricted Stock Units |
| Babler Martin Director | Mar 7, 2024 | 2,500 | $98.23K | Mar 7, 2024 | Stock Option Exercise |
| Smith Sean Officer | Mar 4, 2024 | 371 | $13.57K | Mar 4, 2024 | Employee Stock Purchase Plan |
| Simpson Todd Director | Feb 9, 2024 | 2,500 | $77.50K | Feb 9, 2024 | Stock Option Exercise |
| Lavelle Erin Director | Feb 6, 2024 | 2,500 | $76.13K | Feb 6, 2024 | Stock Option Exercise |